Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina BoniMary J FidlerHendrik-Tobias ArkenauAlexander SpiraFunda Meric-BernstamNataliya UbohaRachel E SanbornRandy F SweisPatricia LoRussoMisako NagasakaJavier García CorbachoShadia JalalJames J HardingStella K KimIris H C MiedemaDanielle J VugtsMarc C HuismanGerben J C ZwezerijnenGuus A M S van DongenCatharina Willemien Menke-van der Houven van OordtSong WangTam DangIvan A ZeinOlga VasiljevaSusan K LymanVirginia PatonAlison HannahJoyce F LiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
CD166 is a novel, ubiquitously expressed target. CX-2009 is the first conditionally activated antibody-drug conjugate to CD166 to demonstrate both translational and clinical activity in a variety of tumor types.